Exhibit 99.1

 

LOGO

Alere Files Form 10-K, Reports Fourth Quarter and

Full Year 2016 Financial Results

 

 

WALTHAM, Mass., June 5, 2017 – Alere Inc. (NYSE: ALR), a global leader in rapid diagnostic tests, today announced that it has filed its Form 10-K and reported its financial results for the fourth quarter and full year ended December 31, 2016.

Full Year 2016 Results

 

    Revenue for the full year 2016 was $2.38 billion, a 3% decrease compared to $2.46 billion in the prior year period.

 

    Non-GAAP organic growth for the full year 2016 was +0.3% or +2.5% excluding Arriva*.

 

    Strong performance in Infectious Disease led by international growth on a constant currency basis included double-digit growth in Latin America, Asia Pacific and Africa. Patient self-testing also achieved double-digit growth in 2016.

 

    Negative impact of foreign currency exchange was $41 million in 2016.

 

    GAAP loss from continuing operations was $(137) million, or $(1.83) per diluted share, for the full year 2016, compared to $(15) million, or $(0.43) per diluted share in the prior year period.

 

    Non-GAAP adjusted EBITDA of $347 million for the full year 2016, a 30% decrease compared to $495 million in the prior year period. The decrease was primarily due to approximately $135 million in merger-related costs, audit and legal fees related to ongoing investigations and legal settlements, as detailed in the Supplemental Financial Information table.

*During the period from November 4, 2016 to December 31, 2016, the Company furnished $9.8 million of Arriva products and services that were subject to the CMS revocation to customers but did not recognize any revenue for such products and services because they were not eligible for reimbursement by CMS at the time the Company furnished them.

“Alere delivered solid 2016 results by maintaining our discipline and staying focused on core business growth as a leader in point-of-care diagnostics. Excluding extraordinary costs and the impact of foreign currency exchange and divestitures, our operating earnings in 2016 were roughly in line with 2015,” said Namal Nawana, CEO of Alere. “We successfully accelerated growth in our global Infectious Disease business in 2016, achieving double-digit sales growth driven by the success of the Alere i molecular platform with an expanded menu of three assays. In addition, we continued to invest in global operations and infrastructure to strengthen the enterprise. We have seen a strong start to 2017 in each of our global business units and look forward to reporting our progress in the first quarter results.”


Revenue

(in millions)

   FY2016      FY2015      % Change  

Cardiometabolic Disease

   $ 622      $ 704        (12 %) 

Infectious Disease

     776        710        9

Toxicology

     609        618        (2 %) 

Other

     140        192        (27 %) 

Consumer Diagnostics

Other Non-reportable*

    

74

143

 

 

    

85

129

 

 

    

(13

10

%) 

License and Royalty

     12        17        (29 %) 
  

 

 

    

 

 

    

 

 

 

Total

   $ 2,376      $ 2,456        (3 %) 
  

 

 

    

 

 

    

 

 

 

 

* Patient self-testing has been reclassified into a separate reporting segment called “Other Non-reportable.”

Fourth Quarter 2016 Results

 

    Total revenue was $597 million, a 3% decrease compared to $617 million in the prior year period.

 

    Global influenza sales were $39 million in the fourth quarter of 2016, a 60% increase compared to $24 million in the prior year period.

 

    Non-GAAP organic growth during the fourth quarter of 2016 was -0.9%, or +3.7% excluding Arriva.

 

    Negative impact of foreign currency exchange was $8 million in the fourth quarter of 2016.

 

    GAAP loss from continuing operations during the fourth quarter of 2016 was $(114) million, or $(1.38) per diluted share, compared to $(22) million, or $(0.31) per diluted share in the prior year period.

 

    Non-GAAP adjusted EBITDA was $82 million in the fourth quarter of 2016, a 10% decrease compared to $91 million in the prior year period. The decrease was primarily due to higher costs as detailed in the Supplemental Financial Information table.

 

Revenue (in millions)    Fourth
Quarter 2016
     Fourth
Quarter 2015
     % Change  

Cardiometabolic Disease

   $ 144      $ 180        (20 %) 

Infectious Disease

     212        189        12

Toxicology

     148        150        (1 %) 

Other

     38        45        (15 %) 

Consumer Diagnostics

Other Non-reportable*

    

18

34

 

 

    

20

31

 

 

    

(11

11

%) 

License and Royalty

     4        3        30
  

 

 

    

 

 

    

 

 

 

Total

   $ 597      $ 617        (3 %) 
  

 

 

    

 

 

    

 

 

 

 

* Patient self-testing has been reclassified into a separate reporting segment called “Other Non-reportable.”

 

Page 2 of 4


Non-GAAP Information

To supplement the financial measures prepared in accordance with U.S. GAAP, the Company uses Non-GAAP adjusted EBITDA and Non-GAAP organic growth, which are non-GAAP financial measures. The reconciliations of Non-GAAP adjusted EBITDA to net income (loss) from continuing operations and Non-GAAP organic growth to revenue, the most directly comparable financial measures calculated and presented in accordance with U.S. GAAP, are shown in the table in this press release. The Company believes Non-GAAP adjusted EBITDA and Non-GAAP organic growth are useful to investors because these metrics are commonly used by investors to assess the unleveraged, pre-tax financial performance and operating results of ongoing business operations. The Company’s management also uses Non-GAAP adjusted EBITDA and Non-GAAP organic growth because the Company’s management also believes that these are useful measures to evaluate the financial performance of the Company based on operational factors. It should also be noted that not all companies calculate Non-GAAP adjusted EBITDA and Non-GAAP organic growth in the same manner and, accordingly, these measures presented in this press release may not be comparable to similar measures used by other companies.

Conference Call

As announced on February 1, 2016, Alere entered into a definitive agreement under which Abbott will acquire Alere, which definitive agreement was amended on April 12, 2017. The transaction is expected to close by the end of the third quarter of 2017, subject to the approval of Alere shareholders and the satisfaction of certain customary closing conditions, including applicable regulatory approvals. Due to the pending transaction, Alere will no longer hold conference calls to discuss its quarterly financial results.

Cautionary Statement Regarding Forward-Looking Statements

This communication contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Readers can identify these statements by forward-looking words such as “preliminary”, “may,” “could,” “should,” “would,” “intend,” “will,” “expect,” “anticipate,” “believe,” “estimate,” “can,” “continue” or similar words. A number of important factors could cause actual results of Alere and its subsidiaries to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, (i) the risk that the proposed merger with Abbott Laboratories (“Abbott”) may not be completed in a timely manner or at all; (ii) the failure to receive, on a timely basis or otherwise, the required approval of the proposed merger with Abbott by Alere’s stockholders, (iii) the possibility that competing offers or acquisition proposals for Alere will be made; (iv) the possibility that any or all of the various conditions to the consummation of the merger may not be satisfied or waived, including the failure to receive any required regulatory approvals from any applicable governmental entities (or any conditions, limitations or restrictions placed on such approvals); (v) the occurrence of any event, change or other circumstance that could give rise to the termination of the Agreement and Plan of Merger, as amended (the “Merger Agreement”) among Alere and Abbott pursuant to which Abbott will acquire Alere, including in circumstances which would require Alere to pay a termination fee or other expenses; (vi) the effect of the announcement or pendency of the transactions contemplated by the Merger Agreement on Alere’s ability to retain

 

Page 3 of 4


and hire key personnel, its ability to maintain relationships with its customers, suppliers and others with whom it does business, or its operating results and business generally; (vii) risks related to diverting management’s attention from Alere’s ongoing business operations; (viii) the risk that stockholder litigation in connection with the transactions contemplated by the Merger Agreement may result in significant costs of defense, indemnification and liability, (ix) the risk that the previously announced review of certain aspects of revenue recognition is not completed in a timely manner or the scope of such review expands, (x) the risk that the failure by Alere to file its Form 10-K for the fiscal year ended December 31, 2016 and Form 10-Q for the fiscal quarter ended in March 31, 2017 in a timely manner could lead to the acceleration of the maturity of certain of Alere’s indebtedness, (xi) the possibility that the previously announced review of certain aspects of revenue recognition uncovers an additional error or errors in revenue recognition or other financial information which require additional adjustments which may be material, or material weaknesses in the Company’s internal controls over financial reporting, (xii) the risk that the Company experiences an acceleration of amounts due under its senior secured credit facility due to the restatement, any circumstances described in Alere’s Current Report on Form 8-K as filed on April 17, 2017, Current Report on Form 8-K as filed on May 22, 2017 or the failure to timely file the Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2017, (xiii) risks relating to the ongoing investigations by the United States Securities and Exchange Commission (the “SEC”) and the United States Department of Justice, (xiv) the risk that these or other risk factors impact the expected timing of the filing of the Form 10-K for the fiscal year ended December 31, 2016 and Form 10-Q for the fiscal quarter ended in March 31, 2017, and (xv) the risk factors detailed in Part I, Item 1A, “Risk Factors,” of our Annual Report on Form 10-K for the fiscal year ended December 31, 2015 (as filed with the SEC on August 8, 2016) and other risk factors identified herein or from time to time in our periodic filings with the SEC. Readers should carefully review these risk factors, and should not place undue reliance on our forward-looking statements. These forward-looking statements are based on information, plans and estimates at the date of this communication. The Company undertakes no obligation to update any forward-looking statements to reflect changes in underlying assumptions or factors, new information, future events or other changes.

About Alere

Alere believes that when diagnosing and monitoring health conditions, Knowing now matters.™ Alere delivers reliable and actionable information by providing rapid diagnostic tests, enhancing clinical and economic healthcare outcomes globally. Headquartered in Waltham, Mass., Alere focuses on rapid diagnostics for cardiometabolic disease, infectious disease and toxicology. For more information on Alere, please visit www.alere.com.

# # #

Investor Relations

Juliet Cunningham

Vice President, Investor Relations

ir@alere.com

858.805.2232

 

Page 4 of 4


Alere Inc. and Subsidiaries

Condensed Consolidated Statements of Operations

(in thousands, except per share amounts)

 

     Three Months Ended December 31,     Twelve Months Ended December 31,  
     2016     2015     2016     2015  

Net product sales and services revenue

   $ 592,553     $ 613,850     $ 2,364,337     $ 2,438,638  

License and royalty revenue

     4,256       3,286       11,998       16,977  
  

 

 

   

 

 

   

 

 

   

 

 

 

Net revenue

     596,809       617,136       2,376,335       2,455,615  

Cost of net revenue

     325,648       368,586       1,286,468       1,347,315  
  

 

 

   

 

 

   

 

 

   

 

 

 

Gross profit

     271,161       248,550       1,089,867       1,108,300  

Gross margin

     45     40     46     45

Operating expenses:

        

Research and development

     25,184       28,228       112,122       119,453  

Selling, general and administrative

     261,431       229,877       966,831       808,595  

Impairment and (gain) loss on disposition, net

     —         8,132       (3,810     50,540  
  

 

 

   

 

 

   

 

 

   

 

 

 

Operating income

     (15,454     (17,687     14,724       129,712  

Interest and other income (expense), net

     (32,137     (60,482     (167,122     (214,254
  

 

 

   

 

 

   

 

 

   

 

 

 

Loss from continuing operations before provision (benefit) for income taxes

     (47,591     (78,169     (152,398     (84,542

Provision (benefit) for income taxes

     83,762       (51,145     35,376       (53,564
  

 

 

   

 

 

   

 

 

   

 

 

 

Income (loss) from continuing operations before equity earnings of unconsolidated entities, net of tax

     (131,353     (27,024     (187,774     (30,978

Equity earnings of unconsolidated entities, net of tax

     17,200       5,210       50,505       15,530  
  

 

 

   

 

 

   

 

 

   

 

 

 

Income (loss) from continuing operations

     (114,153     (21,814     (137,269     (15,448

Income from discontinued operations, net of tax

     —         2,736       —         219,513  
  

 

 

   

 

 

   

 

 

   

 

 

 

Net income

     (114,153     (19,078     (137,269     204,065  

Less: Net income attributable to non-controlling interests

     (103     (5     350       381  
  

 

 

   

 

 

   

 

 

   

 

 

 

Net income attributable to Alere Inc. and Subsidiaries

     (114,050     (19,073     (137,619     203,684  

Preferred stock dividends

     (5,367     (5,366     (21,350     (21,293
  

 

 

   

 

 

   

 

 

   

 

 

 

Net income available to common stockholders

   $ (119,417   $ (24,439   $ (158,969   $ 182,391  
  

 

 

   

 

 

   

 

 

   

 

 

 

Basic net income per common share:

        

Income (loss) from continuing operations

   $ (1.38   $ (0.31   $ (1.83   $ (0.43

Income from discontinued operations

     —             2.57  
  

 

 

   

 

 

   

 

 

   

 

 

 

Basic and diluted net income per common share

   $ (1.38   $ (0.31   $ (1.83   $ 2.14  
  

 

 

   

 

 

   

 

 

   

 

 

 

Diluted net income per common share:

        

Income (loss) from continuing operations

   $ (1.38   $ (0.31   $ (1.83   $ (0.43

Income from discontinued operations

     —           —         2.57  
  

 

 

   

 

 

   

 

 

   

 

 

 

Diluted net income per common share

   $ (1.38   $ (0.31   $ (1.83   $ 2.14  
  

 

 

   

 

 

   

 

 

   

 

 

 

Weighted average shares - basic

     86,955       85,953       86,796       85,420  
  

 

 

   

 

 

   

 

 

   

 

 

 

Weighted average shares - diluted

     86,955       85,953       86,796       85,420  
  

 

 

   

 

 

   

 

 

   

 

 

 


Alere Inc. and Subsidiaries

Condensed Consolidated Balance Sheets

(in thousands)

 

     December 31,      December 31,  
     2016      2015  

ASSETS

     

CURRENT ASSETS:

     

Cash and cash equivalents

   $ 567,215      $ 502,200  

Restricted cash

     51,550        5,694  

Marketable securities

     76        164  

Accounts receivable, net

     413,535        436,924  

Inventories, net

     308,920        350,949  

Prepaid expenses and other current assets

     118,607        114,514  

Assets held for sale

     —          4,165  
  

 

 

    

 

 

 

Total current assets

     1,459,903        1,414,610  

Property, Plant and Equipment, net

     441,190        446,039  

Goodwill and other intangible assets, net

     3,592,107        3,862,306  

Restricted Cash- non-current

     2,171        43,228  

Other non-current assets

     152,908        138,640  

Assets held for sale - non-current

     —          13,337  
  

 

 

    

 

 

 

Total assets

   $ 5,648,279      $ 5,918,160  
  

 

 

    

 

 

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

     

CURRENT LIABILITIES:

     

Short-term debt and current portions of long-term debt and capital lease obligations

   $ 85,434      $ 203,954  

Liabilities related to assets held for sale

     —          363  

Other current liabilities

     590,722        518,389  
  

 

 

    

 

 

 

Total current liabilities

     676,156        722,706  
  

 

 

    

 

 

 

LONG-TERM LIABILITIES:

     

Long-term debt and capital lease obligations, net of current portions

     2,865,426        2,838,347  

Deferred tax liabilities

     119,098        147,618  

Other long-term liabilities

     155,992        154,193  

Liabilities related to assets held for sale - non-current

     —          —    
  

 

 

    

 

 

 

Total long-term liabilities

     3,140,516        3,140,158  
  

 

 

    

 

 

 

TOTAL EQUITY

     1,831,607        2,055,296  
  

 

 

    

 

 

 

Total liabilities and equity

   $ 5,648,279      $ 5,918,160  
  

 

 

    

 

 

 


Alere Inc. and Subsidiaries

Selected Consolidated Revenues

(in thousands)

 

     Three Months Ended December 31,      % Change  
     2016      2015      2016 v. 2015  

Professional diagnostics segment (1)

        

Cardiometabolic

   $ 143,569      $ 180,163        -20

Infectious disease

     211,509        188,609        12

Toxicology

     147,785        149,540        -1

Other

     38,020        44,927        -15
  

 

 

    

 

 

    

Total professional diagnostics segment

     540,883        563,239        -4

Consumer diagnostics segment (1)

     17,569        19,768        -11

Other Non-reportable

     34,101        30,843        11

License and royalty revenue

     4,256        3,286        30
  

 

 

    

 

 

    

Net revenue

   $ 596,809      $ 617,136        -3
  

 

 

    

 

 

    
     Twelve Months Ended December 31,      % Change  
     2016      2015      2016 v. 2015  

Professional diagnostics segment (1)

        

Cardiometabolic

   $ 622,468      $ 703,553        -12

Infectious disease

     776,153        710,178        9

Toxicology

     608,635        618,362        -2

Other

     140,426        192,321        -27
  

 

 

    

 

 

    

Total professional diagnostics segment

     2,147,682        2,224,414        -3

Consumer diagnostics segment (1)

     74,152        85,128        -13

Other Non-reportable

     142,503        129,096        10

License and royalty revenue

     11,998        16,977        -29
  

 

 

    

 

 

    

Net revenue

   $ 2,376,335      $ 2,455,615        -3
  

 

 

    

 

 

    

 

(1) Revenues have been restated for the impact of restatements made during the preparation of our consolidated financial statements for 2016. For more information on these restatements see Note 2 in our Form 10-K.


Alere Inc. and Subsidiaries

Reconciliation of Net Income (Loss) to Non-GAAP EBITDA

(in thousands)

 

     Three Months Ended December 31,  
     2016     2015  

Net Income (loss) (1)

   $ (114,153   $ (19,078

Less: Income from discontinued operations, net of tax

     —         2,736  
  

 

 

   

 

 

 

Loss from continuing operations

     (114,153     (21,814

Adjustment related to acquired software license contracts

     —         —    

Income tax provision (benefit)

     83,762       (51,145

Depreciation and amortization

     71,467       75,719  

Interest, net

     42,342       57,954  

Non-cash stock-based compensation expense

     10,681       6,795  

Non-cash fair value adjustments to acquisition-related contingent consideration

     (1,419     (5,703

Impairment and (gain) loss on dispositions, net

     (11,152     8,132  

Non-cash INRatio product recall expenses

     —         21,100  

Other

     —         (40
  

 

 

   

 

 

 

Non-GAAP Adjusted EBITDA

   $ 81,528     $ 90,998  
  

 

 

   

 

 

 

 

(1) Net income (loss) for the three months ended December 31, 2015 includes $16.7 million of cash costs asssociated with the voluntary withdrawal of INRatio products, restructuring charges of $4.3 million, $2.8 million of costs associated with business dispositions, $0.1 million of acquisition-related costs which have not been added back for purposes of computing Non-GAAP Adjusted EBITDA. The three months ended December 31, 2016 includes $22.1 million of Abbott integration costs, $14.3 million for a legal settlement accrual, $15.5 million of charges related to governmental investigations, non-interest related restructuring charges of $10.1 million, $0.5 million of cash costs associated with the voluntary withdrawal of InRatio product, and $0.1 million of acquisition-related costs which have not been added back for purposes of computing Non-GAAP Adjusted EBITDA.

 

     Twelve Months Ended December 31,  
     2016     2015  

Net Income (loss) (1)

   $ (137,269   $ 204,065  

Less: Income from discontinued operations, net of tax

     —         219,513  
  

 

 

   

 

 

 

Loss from continuing operations

     (137,269     (15,448

Adjustment related to acquired software license contracts

     —         877  

Income tax provision (benefit)

     35,376       (53,564

Depreciation and amortization

     285,884       309,684  

Interest, net

     168,320       212,551  

Non-cash stock-based compensation expense

     41,796       26,391  

Non-cash fair value adjustments to acquisition-related contingent consideration

     (13,308     (57,613

Impairment and (gain) loss on dispositions, net

     (33,683     50,540  

Non-cash INRatio product recall expenses

     —         21,100  

Other

     —         622  
  

 

 

   

 

 

 

Non-GAAP Adjusted EBITDA

   $ 347,116     $ 495,139  
  

 

 

   

 

 

 

 

(1) Net income (loss) for the twelve months ended December 31, 2015 includes $16.7 million of cash costs associated with the voluntary withdrawal of INRatio products, restructuring charges of $15.6 million, $9.3 million of costs associated with business dispositions, and $0.5 million of acquisition-related costs which have not been added back for purposes of computing Non-GAAP Adjusted EBITDA. The twelve months ended December 31, 2016 includes $60.3 million of Abbott integration costs, restructuring charges of $37.9 million, $38.2 million of charges related to governmental investigations, $35.2 million for a legal settlement accrual, $6.0 million of acquisition-related costs, $1.8 million of cash costs associated with the withdrawal of InRatio product and $1.0 million of costs associated with business dispositions which have not been added back for purposes of computing Non-GAAP Adjusted EBITDA.


Alere Inc. and Subsidiaries

Reconciliation of Non-GAAP Organic Revenue Growth

(in thousands)

 

     Three Months Ended December 31,     % Change
2016 v. 2015
 
     2016     2015    

Net revenue

   $ 596,809     $ 617,136       -3.3

Impact of foreign currency exchange

     7,830       —      

Impact of acquisitons & dispositions

     (1,453     (8,234  
  

 

 

   

 

 

   

Non-GAAP organic net revenue

   $ 603,186     $ 608,902       -0.9
  

 

 

   

 

 

   

Arriva revenue

     (11,622     (38,592  
  

 

 

   

 

 

   

Non-GAAP organic net revenue (excluding Arriva)

   $ 591,564     $ 570,310       3.7
  

 

 

   

 

 

   
     Twelve Months Ended December 31,     % Change  
     2016     2015     2016 v. 2015  

Net revenue

   $ 2,376,335     $ 2,455,615       -3.2

Impact of foreign currency exchange

     40,543       —      

Impact of acquisitons & dispositions

     (13,984     (60,414  
  

 

 

   

 

 

   

Non-GAAP organic net revenue

   $ 2,402,894     $ 2,395,201       0.3
  

 

 

   

 

 

   

Arriva revenue

     (99,887     (148,538  
  

 

 

   

 

 

   

Non-GAAP organic net revenue (excluding Arriva)

   $ 2,303,007     $ 2,246,663       2.5
  

 

 

   

 

 

   


Alere Inc. and Subsidiaries

Supplemental Financial Information

(in thousands, except per share amounts)

 

     Three months ended December 31, 2016  
     Cost of Net
Revenue
     Research and
Development
     Selling, General
&
Administrative
    Impairment,
net of loss on
disposition
     Interest and
other
income, net
     Provision for
income taxes
     Equity earnings of
unconsolidated entities,
net of tax
    Net Income1  

Amortization of acquisition-related intangible assets

   $ 12,281      $ 922      $ 31,384     $ —        $ —        $ —        $ —       $ (44,587

Restructuring charges

     2,090        512        7,535       —          —          —          —         (10,136

Impairment Charges

     —          —          193       —          —          —          —         (193

Stock-based compensation expense

     518        531        9,633       —          —          —          —         (10,681

Acquisition-related costs

     —          —          72       —          —          —          —         (72

Fair value adjustments to acquisition-related contingent consideration

     —          —          (1,419     —          —          —          —         1,419  

Costs associated with potential business dispositions

     —          —          42       —          —          —          —         (42

Impairment and (gain) loss on disposition, net

     —          —          —         —          —          —          (11,152     11,152  

Amortization - Unconsolidated Subs

     —          —          —         —          —          —          46       (46

Audit and legal fees related to on-going governmental investigations

     —          —          15,493       —          1,697        —          —         (17,190

Abbott transaction related expenses

     —          —          22,064       —          —          —          —         (22,064

INRatio recall expense

     2,481        —          (1,300     —          —          —          —         (1,181

Legal settlement accrual

     —          —          14,300       —          —          —          —         (14,300

Income tax effects on items above

     —          —          —         —          —          70,892        —         (70,892
  

 

 

    

 

 

    

 

 

   

 

 

    

 

 

    

 

 

    

 

 

   

 

 

 

Total of Supplemental Information

   $ 17,370      $ 1,965      $ 97,998     $ —        $ 1,697      $ 70,892      $ (11,106   $ (178,815
  

 

 

    

 

 

    

 

 

   

 

 

    

 

 

    

 

 

    

 

 

   

 

 

 

Impact of above items on EPS numerator

                      $ —    

Impact of above items on EPS denominator

                        —    

 

1) All impacts are shown as pre-tax with aggregate tax effect displayed as “Income tax effects on items above”

 

     Twelve months ended December 31, 2016  
     Cost of Net
Revenue
     Research and
Development
     Selling, General
&
Administrative
    Impairment,
net of loss on
disposition
    Interest and
other
income, net
     Provision for
income taxes
    Equity earnings of
unconsolidated entities,
net of tax
    Net Income1  

Amortization of acquisition-related intangible assets

   $ 49,616      $ 3,685      $ 127,253     $ —       $ —        $ —       $ —       $ (180,553

Restructuring charges

     5,991        4,052        27,831       —         —          —         —         (37,874

Impairment Charges

     85        —          193       —         —          —         —         (278

Stock-based compensation expense

     2,054        1,904        37,838       —         —          —         —         (41,796

Acquisition-related costs

     —          5,000        1,030       —         —          —         —         (6,030

Fair value adjustments to acquisition-related contingent consideration

     —          —          (13,308     —         —          —         —         13,308  

Costs associated with potential business dispositions

     7        —          995       —         —          —         —         (1,002

Impairment and (gain) loss on disposition, net

     —          —          —         (3,810     —          —         (29,873     33,683  

Amortization - Unconsolidated Subs

     —          —          —         —         —          —         275       (275

Audit and legal fees related to on-going governmental investigations

     —          —          38,215       —         4,509        —         —         (42,725

Abbott transaction related expenses

     —          —          60,266       —         —          —         —         (60,266

INRatio recall expense

     4,581        —          —         —         —          —         —         (4,581

Legal settlement accrual

     —          —          35,175       —         —          —         —         (35,175

Income tax effects on items above

     —          —          —         —         —          (21,397     —         21,397  
  

 

 

    

 

 

    

 

 

   

 

 

   

 

 

    

 

 

   

 

 

   

 

 

 

Total of Supplemental Information

   $ 62,333      $ 14,641      $ 315,488     $ (3,810   $ 4,509      $ (21,397   $ (29,598   $ (342,166
  

 

 

    

 

 

    

 

 

   

 

 

   

 

 

    

 

 

   

 

 

   

 

 

 

Impact of above items on EPS numerator

                    $ (1,035

Impact of above items on EPS denominator

                      (2,279

 

1) All impacts are shown as pre-tax with aggregate tax effect displayed as “Income tax effects on items above”

View differences made from one to another to evaluate Alere Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Alere Inc..

Continue

Never Miss A New SEC Filing Again


Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report
Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.

Continue

We Highlighted This SEC Filing For You


SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report
Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.

Continue

Widen Your SEC Filing Reading Experience


Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report
Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view

Continue

Uncover Actionable Information Inside SEC Filings


SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report
Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q

Continue

Adobe PDF, Microsoft Word and Excel Downloads


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats
Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis

Continue

FREE Financial Statements


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report
Last10K.com Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Intrinsic Value Calculator


Intrinsic Value Calculator
Screenshot of intrinsic value for AT&T (2019)
Last10K.com Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not

Continue

Financial Stability Report


Financial Stability Report
Screenshot of financial stability report for Coco-Cola (2019)
Last10K.com Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity

Continue

Get a Better Picture of a Company's Performance


Financial Ratios
Available Financial Ratios
Last10K.com Member Feature

See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years

Continue

Log in with your credentials

or    

Forgot your details?

Create Account